Clinical trial
V501 Efficacy Study in Women Aged 18 to 26 (V501-027)
NCT00378560 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00378560 |
|---|---|
| Title | V501 Efficacy Study in Women Aged 18 to 26 (V501-027) |
| Official title | V501 Phase II Efficacy Study in Women Aged 18 to 26 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HPV Infections |
| Intervention type | Biological |
| Interventions | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo |
| Enrollment | 1,021 |
| Start date | Jun 12, 2006 |
| Primary completion | Sep 16, 2009 |
| Completion | Sep 16, 2009 |
| First posted | Sep 20, 2006 |
| Last update posted | Apr 17, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: